Patent intelligence · WO
WO 2005026133
ISOXAZOLES UTILISES COMME INHIBITEURS DE PEPTIDE DEFORMALYSE
ISOXAZOLES UTILISES COMME INHIBITEURS DE PEPTIDE DEFORMALYSE
Patent details — WO 2005026133
- Jurisdiction
- WO
- Status
- expired
- Grant date
- Mar 24, 2005
- Expiration
- Mar 19, 2025
- Applicant
- ARPIDA AS [DK]
- CPC classes
- A61K 31/ 42 A I, A61K31/42, A61P 31/ 00 A I, A61P/3100
Quick answer
WO 2005026133 (ISOXAZOLES UTILISES COMME INHIBITEURS DE PEPTIDE DEFORMALYSE) is held by ARPIDA AS [DK]. Status: expired. Granted Mar 24, 2005. Expires Mar 19, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARPIDA AS [DK]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 42 A I, A61K31/42, A61P 31/ 00 A I, A61P/3100, A61P/3104, A61P/4300
More from ARPIDA AS [DK]
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 2005026133?
WO 2005026133 (ISOXAZOLES UTILISES COMME INHIBITEURS DE PEPTIDE DEFORMALYSE) is held by ARPIDA AS [DK]. Status: expired. Granted Mar 24, 2005. Expires Mar 19, 2025 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2005026133?
ARPIDA AS [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does WO 2005026133 expire?
Our index shows an expiration date of Mar 19, 2025 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.